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Abstract 
Background: Pakistan is classified as one of the high multi-drug resistant tuberculosis (MDR-TB) burden countries. 
A poorly regulated private sector, over-prescription of antibiotics and self-medication has led to augmented rates of 
drug-resistance in the country. Pakistan’s first national anti-tuberculosis drug resistance survey identified high preva-
lence of fluoroquinolone resistance among MDR-TB patients. Further institutional evidence of fluoroquinolone drug-
resistance can support re-evaluation of treatment regimens as well as invigorate efforts to control antibiotic resistance 
in the country.
Findings: In this study, data for drug-susceptibility testing (DST) was retrospectively analyzed for a total of 133 
patients receiving MDR-TB treatment at the Chest Department of Jinnah Postgraduate Medical Center, Karachi, 
Pakistan. Frequency analyses for resistance patterns was carried out and association of fluoroquinolone (ofloxacin) 
resistance with demographics and past TB treatment category were assessed. Within first-line drugs, resistance to 
isoniazid was detected in 97.7% of cases, followed by rifampicin (96.9%), pyrazinamide (86.4%), ethambutol (69.2%) 
and streptomycin (64.6%). Within second-line drugs, ofloxacin resistance was detected in 34.6% of cases. Resistance 
to ethionamide and amikacin was 2.3% and 1.6%, respectively. Combined resistance of oflaxacin and isoniazid was 
detected in 33.9% of cases. Age, gender and past TB treatment category were not significantly associated with resist-
ance to ofloxacin.
Conclusion: Fluoroquinolone resistance was observed in an alarmingly high proportion of MDR-TB cases. Our results 
suggest caution in their use for empirical management of MDR-TB cases and recommended treatment regimens for 
MDR-TB may require re-evaluation. Greater engagement of private providers and stringent pharmacy regulations are 
urgently required.
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Findings
Background
Globally, emerging drug resistance poses a serious threat 
to the control of tuberculosis (TB) [1]. In 2012, the World 
Health Organization (WHO) estimated 450,000 (range 
300,000–600,000) new cases of multidrug-resistant TB 
(MDR-TB) in the world; 3.6% of newly diagnosed TB 
cases, causing an estimated 170,000 (range 102,000–
142,000) deaths [2]. Pakistan contributes to 69% of the 
MDR-TB burden in the Eastern Mediterranean Region 
(EMRO), with an estimated 11,000–29,000 cases occur-
ring in 2012 [2]. Over the past few years the country has 
also reported an increasing trend of Extensively Drug 
Resistance disease (XDR-TB) that includes resistance 
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to fluoroquinolones and at least one other second-line 
injectable, in addition to MDR-TB [3].
Fluoroquinolone resistance is of particular public 
health importance as it is a widely prescribed antibiotic 
for treatment of common respiratory tract infections. 
There is a rampant and poorly regulated private health-
care sector in Pakistan, where over-prescription of fluo-
roquinolones by general practitioners, over-the-counter 
sales at private pharmacies and self-medication by 
patients occur commonly [4]. Recently published findings 
from the first national anti-tuberculosis drug resistance 
survey of Pakistan identified fluoroquinolone resistance 
of 26.6% (95% CI 18.0–36.7) among a total sample of 96 
MDR-TB cases [5]. Evidence suggests that occurrence 
of fluoroquinolone resistance is on the rise, with a study 
reporting increase in its prevalence from 17.4% in 2005, 
to 53.9% in 2014 among MDR-TB patients [6].
Fluoroquinolones are the mainstay of treatment of 
MDR-TB and resistance has been associated with poor 
treatment outcomes for MDR-TB patients [6]. Ris-
ing fluoroquinolone resistance is, therefore, of serious 
concern for the management of MDR-TB patients, par-
ticularly at a time when Pakistan is scaling-up its Pro-
grammatic Management of Drug-resistant TB (PMDT) 
program [7]. Scale-up of Xpert MTB/RIF testing in the 
country has significantly facilitated diagnosis of MDR-TB 
since resistance to rifampicin can be identified at the time 
of diagnosis [8]. However, patients initially require empir-
ical treatment as drug-susceptibility testing (DST) results 
to fluoroquinolones and other second-line drugs require 
6–8  weeks by conventional methods. A lack of clinical 
response to medication can be alarming for both patients 
and providers [9]. In the setting of increasing resistance 
to fluoroquinolones, current combinations of empirical 
therapy used by MDR-TB programs may require revalu-
ation. Further institutional evidence of fluoroquinolone 
drug-resistance among MDR-TB patients can support 
such recommendations as well as boost efforts to control 
antibiotic resistance in the country. This study describes 
the drug-resistance patterns of microbial isolates from 
MDR-TB suspects from a tertiary-care facility in Karachi, 
Pakistan from 2009 to 2012.
Methods
We analyzed de-identified, retrospective data of patients 
receiving MDR-TB treatment at Jinnah Postgradu-
ate Medical Center, the largest public-sector hospital in 
Pakistan’s southern Sind province, between 2009 and 
2012. All patients enrolled on MDR-TB program had a 
history of TB treatment and were included in the analy-
sis using convenience sampling. Sputum was obtained 
from the patients prior to MDR-TB treatment initiation 
and DST of Mycobacterium tuberculosis isolates was 
carried out at the Aga Khan University clinical labora-
tory, a technical partnering facility for the National TB 
Program (NTP). Demographic and clinical histories of 
the patients were obtained from the hospital records. 
Treatment history was categorized as prior history of 
Category I TB treatment (four-drug anti-TB treatment 
regimen) and Category II (four-drug anti-TB treatment 
regimen +  streptomycin). Frequency analyses for resist-
ance patterns and demographic variables were carried 
out. The association of ofloxacin (a second-generation 
fluoroquinolone) resistance with age was investigated 
using Student’s t test. Chi squared tests were conducted 
to investigate the association of ofloxacin resistance with 
gender and treatment history. Statistical analyses were 
carried out using Stata/IC 12.0 (Stata Corp, College Sta-
tion, TX, USA).
Results
A total of 133 patients receiving MDR-TB treatment were 
included in the study. Median age of the patients was 16 
(IQR 10–26) and 51.1% were male (Table 1).
Within first-line drugs, resistance to isoniazid was 
reported in 97.7% of cases followed by rifampicin (96.9%), 
pyrazinamide (86.4%), ethambutol (69.2%) and strepto-
mycin (64.6%) (Table 2).
Within second-line drugs, ofloxacin resistance was 
observed in 34.6% of cases. Resistance to ethionamide 
and amikacin was 2.3 and 1.6%, respectively (Table  2). 
Combined resistance to ofloxacin and isoniazid was 
reported in 33.9% of cases (Table 2). Ofloxacin resistance 
was more commonly observed in patients with history 
of Category I treatment (54.3%) compared to Category 
II (40.7%), however, the difference was not statistically 
significant (p value 0.26). Age (p value 0.92) and gen-
der (p value 0.85) were not significantly associated with 
ofloxacin resistance. A total of 3 cases were found to have 
XDR-TB.
Table 1 Demographic characteristics of  MDR-TB patients 




 9–14 10 (8)
 15–29 71 (54)
 30–44 33 (25)
 45< 19 (14)
Gender
 Male 68 (51.1)
 Female 65 (48.9)
Total 133
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Discussion
Our results support findings from previously reported 
studies and the national anti-TB drug resistance survey, 
highlighting growing resistance to fluoroquinolones in 
Pakistan. This is the first study describing institutional 
evidence from an MDR-TB treatment facility of the high 
prevalence of fluoroquinolone resistance among MDR-TB 
cases. Resistance was not associated with age, gender or 
history of TB treatment, suggesting that resistance may be 
widespread within this patient population. These findings 
raise concerns for the outcomes of MDR-TB patients and 
for empirical treatment, following rifampicin resistance 
identification through an Xpert MTB/RIF assay. Recom-
mended treatment regimens for MDR-TB may therefore 
require revaluation for improved treatment outcomes and 
to curtail development of further drug-resistance.
Given the above scenario, several public health policy 
measures and programmatic interventions can be of 
benefit. Firstly, the use of antibiotics, particularly fluoro-
quinolones needs to be strongly regulated. This is likely 
to be a major challenge, given Pakistan’s large and frag-
mented private healthcare sector. A regulation restrict-
ing over-the-counter sale of antibiotics also needs to be 
introduced, the practical implementation of which could 
be difficult. Secondly, strategies to engage with the pri-
vate-sector providers more comprehensively need to be 
explored. Recent initiatives proposed by the National 
TB Control program are encouraging [10]. Under novel 
public–private mix approaches, local networks and part-
nerships can be created where private providers receive 
medication through provincial TB control programs for 
patients and in turn, help to increase case-notification. 
Greater efforts should be in place to collaborate with 
general practitioners, especially with family practition-
ers operating in small clinics in urban areas. Trainings 
should be conducted on NTP guidelines for TB case-
detection and treatment as well as on more judicious use 
of antibiotics for treatment of common infections, with 
a special emphasis on restricting use of fluoroquinolo-
nes. Medical associations, including those representing 
infectious disease specialists, pulmonologists as well as 
pharmacists need to be play a more active role in com-
municating this message to providers and to the public. 
Finally, MDR-TB programs will require greater efforts to 
improve case-holding and ensuring treatment comple-
tion for enrolled patients, as PMDT services expand in 
the country. Community-based solutions and behavioral 
economics approaches such as the use of food-baskets 
and other incentives for treatment compliance may be 
of benefit [11]. Early case-detection through scale-up of 
Xpert MTB/RIF testing may help improve treatment out-
comes as well as limit transmission of resistant strains. 
This study was limited by the absence of DST results for 
third and fourth generation fluoroquinolones for assess-
ing cross-resistance with ofloxacin of M. tuberculosis iso-
lates. In addition, limited patient history was available, 
such as prior history of quinolone use, to further investi-
gate risk factors and clinical correlates to fluoroquinolone 
resistance. We recommend further studies to evaluate 
MDR-TB treatment outcomes and their association with 
fluoroquinolone resistance among DR-TB patients.
Conclusions
Fluoroquinolone resistance was observed in an alarm-
ingly high proportion of MDR-TB cases. Our results 
suggest caution in their use for empirical management 
of MDR-TB cases (particularly second-generation) and 
therefore recommended treatment regimens for MDR-
TB may require revaluation. Engaging private sector 
providers in TB case-detection and stringent pharmacy 
regulations are required to prevent increased resistance 
to fluoroquinolones in Pakistan.
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Table 2 Resistance to  first and  second-line anti-tubercu-
lous medication among  MDR-TB patients at  Jinnah Post-




Any resistance (first line drugs)
 Isoniazid (H) 130 (97.7)
 Rifampicin (R) 129 (96.9)
 Pyrazinamide (Z) 115 (86.4)
 Ethambutol (E) 92 (69.2)
 Streptomycin (S) 86 (64.6)
Any resistance (second line drugs)
 Kanamycin (Km) 1 (0.8)
 Amikacin (Am) 2 (1.5)
 Capreomycin (Cm) 2 (1.5)
 Ofloxacin (Ofx) 49 (34.6)
 Ethionamide (Eto) 3 (2.3)
 Cycloserine (Cs) 1 (0.8)
Combined resistance of H with other drugs
 H + Z 114 (85.7)
 H + E 91 (68.4)
 H + S 86 (64.7)
 H + Z + E 90 (67.7)
 H + Z + E + S 67 (50.4)
 H + Ofx 45 (33.9)
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